Immune Oncology Articles & Analysis
24 news found
Under the agreement, Chimeric gains exclusive global rights to the CORE-NK platform for oncology, where Chimeric and CWRU are currently advancing multiple product candidates in Dr Wald’s laboratory under the recently announced Sponsored Research Agreement. Chimeric also receives exclusive global rights to the CORE-NK platform for immune disorders and viral ...
iBio is jockeying for position as a leading player in Al-powered drug discovery while also expanding its immuno-oncology pipeline after closing on the acquisition of multiple assets from its partner, RubrYc Therapeutics. ...
The transaction included RubrYc's artificial intelligence (“AI”)-driven Discovery Engine; its proprietary humanized antibody library; all rights, with no future milestone payment or royalty obligations, to the two immuno-oncology assets previously licensed in the partnership; and four new immunotherapy candidates. ...
The study was conducted as a collaboration between Atrium Health Levine Cancer Institute, Sanofi, and GeneCentric and evaluated real-world data from patients diagnosed with renal cell carcinoma (RCC) who were treated with immune-oncology agents. Results suggest that common and distinct immune-related response markers for IL-2 and anti-PD-(L)1 ...
Marion and Bertrand will be bringing their commercial and financial experience to further structure Ariana’s exponential growth, as the company continues to expand its xAI-driven drug development partnerships in Oncology, CNS, auto-immune, gastro-enterology and other therapeutic areas, as well as its Real-World Evidence business leveraging its 8 Billion+ ...
Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncology Scientific Advisory Board to provide guidance on the Company’s development strategy across assets and assessment of emerging technologies Heidelberg, Germany, June 30, 2022 – Affimed N.V. ...
(Nasdaq: NEXI) and Zephyr AI (Zephyr) today announced a strategic partnership focusing on the discovery and validation of novel targets for new T-cell-mediated therapies in oncology. Combining Zephyr’s proprietary artificial intelligence (AI) and algorithmic technology with NexImmune’s Artificial Immune Modulation (AIM) nanoparticle technology, the ...
” Aclys is a leader in the emerging field of precision immune medicine. Aclys utilizes a proprietary set of patient molecular data to select differentiated targets and create precision biologics with the safety profile and response rates only achievable with precision biologics. ...
The Piedmont Study paired highly curated real-world clinical and demographic data with bulk tumor RNA transcriptome analysis from patients with NSCLC, which was analyzed using GeneCentric’s RNA-based Tumor and Immune Micro-Environment (rT(I)ME) Explorer platform. “There has been great progress with the development of new treatment options for patients with locally ...
“The EXIS platform offers unprecedented in vitro access to a functional human immune system. We’ve built a platform that enables promising science to be rapidly advanced into new patient therapies,” said Dr. ...
“The EXIS platform offers unprecedented in vitro access to a functional human immune system. We’ve built a platform that enables promising science to be rapidly advanced into new patient therapies,” said Dr. ...
About the rT(I)ME Explorer Platform GeneCentric’s broad pipeline of novel predictive response signatures has been built over the past decade using its proprietary RNA-based Tumor and Immune Micro-Environment (rT(I)ME) Explorer bioinformatics platform. These RNA-based response signatures allow for improved patient selection for new and existing targeted and ...
The team of researchers and specialists is currently working to further expand the medical use of the product in the field of transplantation, hemato-oncology and immune diseases. To this end, the expansion of the production site in Gräfelfing is being driven forward: “We are growing at the site, expanding production capacities. ...
Amlitelimab is a fully human non-depleting monoclonal antibody that binds to OX40-Ligand, a key immune regulator, and has the potential to be a first-in-class treatment for a range of immune-mediated diseases and inflammatory disorders, including moderate-tosevere atopic dermatitis. By targeting OX40-Ligand, amlitelimab aims to restore immune ...
(PsiOxus), a tumor re-engineering company, today announced that they will present key safety and translational data from their first-in-human phase 1 FORTITUDE clinical study at the European Society for Medical Oncology(ESMO) Congress 2021 this week. Data from the completed monotherapy dose-escalation part of the FORTITUDE study, initiated in 2019 to assess the safety and ...
/USA – 14 April 2021: PsiOxus Therapeutics, Ltd. (PsiOxus), a clinical stage oncology company re-programming the tumor microenvironment to overcome the central challenge of resistance to therapy, and bluebird bio, Inc. ...
Actym's SAB comprises world-renowned subject matter experts in immuno-oncology, innate immunity, microbiology, novel drug discovery and development. ...
This strategic partnership with BIF provides translational support in antibody characterisation and development for Biosceptre’s targeted therapeutic and immune-oncology development programs. “UTS stands as one of Australia’s most progressive universities and Biosceptre is delighted to be collaborating with them in the establishment of this new ...
Biosceptre is developing anti-cancer therapies – in particular, targeted therapeutics and immune-oncology products targeting most types of cancers, with the goal of bringing novel treatments to patients suffering from a wide range of malignancies. ...
Biosceptre, a biopharmaceutical company developing targeted therapeutics and immune-oncology products, has acquired the exclusive rights to Carina Biotech’s nfP2X7-targeted CAR-T cells and associated intellectual property, which has shown encouraging cancer-killing capacity against a number of cancers in pre-clinical testing. ...